[The role of angiogenic factors in preeclampsia]

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Cardiovascular Research

Background:

• Preeclampsia is a major pregnancy complication with unclear etiology.
• Research in the 2000s focused on angiogenesis, particularly placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1).
• Antiangiogenic factors are elevated, and proangiogenic factors are decreased in preeclampsia, preceding clinical symptoms.

Purpose of the Study:

• To investigate the role of placental growth factor and soluble fms-like tyrosine kinase-1 in preeclampsia.
• To explore the potential of these factors in predicting and treating preeclampsia.
• To highlight the significance of endothelial dysfunction in the symptomatic stage.

Main Methods:

• Analysis of maternal blood samples for angiogenic factors.
• Review of studies focusing on placental growth factor and soluble fms-like tyrosine kinase-1 concentrations.
• Evaluation of rapid tests for point-of-care detection.

Main Results:

• Increased concentrations of antiangiogenic factors (like sFlt-1) and decreased concentrations of proangiogenic factors (like PlGF) are observed in preeclampsia.
• These angiogenic imbalances are detectable before clinical symptoms manifest.
• Endothelial dysfunction is linked to antiangiogenic proteins in symptomatic preeclampsia.

Conclusions:

• Placental growth factor and soluble fms-like tyrosine kinase-1 play crucial roles in preeclampsia.
• Point-of-care detection of PlGF and sFlt-1 can aid in preeclampsia prediction.
• Removal of sFlt-1 is a potential therapeutic strategy for early-onset preeclampsia.